According to business intelligence provider GBI (GlobalBusinessIntelligence) Research In 2013, The US treatment market for rheumatoid arthritis (RA) was $6.4 billion and which get rising to $9.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.5%. Resaon behind this sudden growth is US’ increasing prevalent population, which is reported to hit 1.68 million by 2020. Consequently, marketcurrently makes up the largest treatmentarea of the eight major pharmaceutical markets (the US, UK, Canada, France, Germany, Spain, Italy and Japan).
Furthermore, the practice of keeping the price of a product or service artificially high in order to encourage favorable perceptions among buyers and disease-modifying therapies into the US’ RA treatment arena, along with new biosimilar products, will also be a contributing factor to its expansion. The lack of regulatory guidelines for their approvals in the US may deter drug manufactures from seeking marketing approval for these products. State law actions can conflict with drug developers preventing clinicians from taking up biosimilar versions of their reference drugs.
The US had the highest ACoT of the eight major markets in 2013, with $5,983, reflecting the country’s higher drug costs in comparison with Canada and the EU. This figure is expected to grow at a CAGR of 3.2% to reach $7,435 by 2020.
